Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model.
Cancer Invest
; 30(3): 243-50, 2012 Mar.
Article
em En
| MEDLINE
| ID: mdl-22360364
ABSTRACT
Herpes-mediated viral oncolysis alone is not sufficient to completely eradicate tumors. In this study we used a replication conditional, endostatin-expressing herpes simplex virus-1 mutant (HSV-Endo) in a murine lung cancer model. We hypothesized that the anti-angiogenic action of endostatin would improve upon the oncolytic effect of HSV-1. HSV-Endo was evaluated in a pulmonary metastases and orthotopic flank model, where there was significantly less tumor burden and reduced microvessel density compared to a control virus. Endostatin expression appears to improve the anti-tumor effect of HSV-1 in a lung cancer model.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Simplexvirus
/
Endostatinas
/
Terapia Viral Oncolítica
/
Neoplasias Pulmonares
/
Neovascularização Patológica
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article